Introduction
Relatively little is known regarding HIV disease natural history and response to antiretroviral treatments among Asian people infected with HIV. The Therapeutics Research, Education and AIDS Training (TREAT) Asia is a cooperative network of clinicians throughout Asia and the Pacific that aims to expand capacity for the broader introduction of HIV/AIDS treatments in the region. The TREAT Asia HIV Observational Database (TAHOD) is the first collaborative study by the TREAT Asia network. TAHOD is a multi-centre, observational study of patients with HIV and aims to assess HIV disease natural history in treated and untreated patients in the Asia and Pacific region.
The objectives of this study are first, to describe TAHOD working procedure and methods; second, to summarise baseline data on patients so far recruited to TAHOD and third, to assess baseline and retrospective data, the rate of CD4 decline in untreated patients and the CD4 and viral load response in patients receiving antiretroviral treatment.
Methods
TAHOD is a collaborative observational cohort study of 11 sites in the Asia and Pacific region (appendix) and aims to recruit and follow-up 200 patients from each site, including both treated and untreated patients. To ensure maximal follow-up rates, recruitment is based on a consecutive series of patients regularly attending a given site.
Ethical approval for the study was obtained from the University of New South Wales Ethics Committee. Each site also approached a local ethics committee for approval. Since all data forwarded to the NCHECR are in an anonymous fashion, informed consent of subjects was not a requirement of sites, except if a requirement of a site's local ethics committee.
Patient demography, stage of disease and antiretroviral treatment data are collected. Retrospective data are collected where available. All data are entirely observational, with test or intervention performed only to clinical guideline at each site. Data are transferred electronically in password-protected WINZIP format to the National Centre in HIV Epidemiology and Clinical Research (NCHECR) for central aggregation and analysis in March and September each year. We present here summaries of the initial baseline data transferred up to November 2003.
Results
By the end of November 2003, 1283 patients had been recruited to TAHOD ( Table 1 ). The majority of the patients were male, with median age 36 years. Chinese, Indian and Thai were the main ethnic groups. Most patients were infected through heterosexual contact; around 8% through homosexual contact and very few (less than 1%) through injecting drug use only.
39% of patients had a previous AIDS defining illnesses (Table 2) , of which, 54% had tuberculosis, and 23% Pneumocystis carinii pneumonia. 9% of all the patients had a CDC category B illness and 5% had Papular pruritic eruption but without AIDS. Most of the patients had a baseline CD4 count between 200-499 cells/µl (48%)and a HIV viral load below 400 copies/ml (62%).
230 patients had more than one CD4 count reported retrospectively while not on antiretroviral treatment. The average rate of CD4 change (per month since the first CD4 count) was -2.8 cells/µl (95% confidence interval, CI -6.4 to 0.7, p=0.1, Table 3 ). Independent factors associated with a higher rate of decreasing CD4 were found to be patients who acquired HIV through heterosexual contact (compared to other route of transmission) and a higher baseline CD4 count (compared to a lower CD4 count at baseline).
Retrospective data were available for 308 patients who had at least one CD4 count before starting highly active antiretroviral therapy (HAART) and another CD4 count six month (within 3 to 9 month) after starting HAART. The mean change was 109.3 cells/µl (95% CI 95.3-123.3, p<0.001, Table 4 ). Independent factors associated with a smaller rate of increasing CD4 included female gender, a higher level of CD4 count before starting HAART and prior treatment with mono or double therapy.
120 patients had at least one HIV viral load test before starting HAART and another viral load test six months (within 3 to 9 month) after starting HAART. 63% of patients had a viral load below the detectable level (<400 copies/ml, Table 5 ). Older age was the only factor associated with a significantly higher rate of achieving undetectable viral load after starting HAART. 
Discussion
Among patients not on antiretroviral treatment, there was a non-significant decrease of CD4 count of 2.8 cells/µl per month with a higher rate of decrease found among patients infected with HIV through heterosexual contact and patients having a higher baseline CD4 count. Among patients who started HAART and had a baseline and six-month CD4 count measurement, the mean six-month CD4 count increase was 109 cells/µl. Predictors of smaller CD4 count increases were female gender, higher CD4 count before starting HAART, and prior treatment with mono or double therapy. Among patients who had started HAART and had a viral load assessment at baseline and six months, 63% of patients had undetectable viral load at six months, with older patients found to be more likely to achieve undetectable level.
Analyses of retrospective data in TAHOD suggest that the overall response to HAART in Asian patient populations is similar to that seen in developed countries. TAHOD has recruited over 1,000 patients, with over 2,000 patients expected when fully recruited. With prospective follow-up TAHOD will be able to assess the natural history of HIV disease, and response to antiretroviral treatments, in patients from the Asia and Pacific region. 
